Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure (70.8% 17/24), microbiological eradication (58.3% 14/24), and day 28 all-cause mortality (12.5% 3/24) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% 4/10, 30.0% 3/10, and 50.0% 5/10, respectively).